National Pension Service Bets on Yuhan Corp: What Should Investors Do? The National Pension Service (NPS), Korea’s largest pension fund, has changed its investment objective in Yuhan Corporation from ‘simple investment’ to ‘general investment’ and increased its stake. This can be interpreted as a positive signal for Yuhan’s future growth potential. This article analyzes the … Read more
Yuhan Corp. Inks $65 Million HCV API Supply Deal Yuhan Corporation has garnered attention with a major supply agreement with Gilead Sciences. This $65 million deal raises questions about its impact on Yuhan’s future. We’ll delve into the contract details, stock price outlook, and actionable insights for investors. What Happened? On August 27, 2025, Yuhan … Read more
Yuhan Corp. and Gilead Sciences Ink $63M API Supply Deal for AIDS Treatment South Korean pharmaceutical giant Yuhan Corp. has captured market attention with a substantial API supply agreement with Gilead Sciences. Valued at approximately $63 million, the deal focuses on providing active pharmaceutical ingredients (API) for an AIDS treatment drug. This article explores the … Read more
ImmuneOncia: A Rising Star in Immuno-Oncology? ImmuneOncia grabbed investor attention in the first half of 2025 with remarkable achievements. Could the imminent domestic commercialization of IMC-001 and the potential licensing of IMC-002 be the catalyst for explosive growth? This article provides an in-depth analysis of ImmuneOncia’s H1 2025 report, highlighting key investment points and future … Read more
Yuhan Corp’s Q2 Earnings: A Deeper Look Yuhan Corporation released its Q2 2025 earnings on July 30, 2025. While operating profit beat market expectations, declines in both revenue and net income have sparked investor concern. This article provides an in-depth analysis of Yuhan’s performance, exploring the underlying factors and discussing potential investment strategies. 1. Yuhan … Read more
Yuhan Corp’s Q2 Earnings: A Comprehensive Guide for Investors Yuhan Corporation’s Q2 2025 earnings announcement is just around the corner. Will they rebound from a disappointing Q1? How is Leclaza performing in the global market? This article analyzes Yuhan’s Q2 earnings outlook, key investment points, and provides a clear action plan for investors. 1. What … Read more